UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: November 2026
Commission
file number: 001-36578
ENLIVEX
LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
As
previously reported, on November 14, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”),
entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”)
in connection with the issuance and sale by the Company in a registered direct offering (the “Offering”) of (i) 5,703,462
of the Company’s ordinary shares, par value NIS 96.00 per share (the “Ordinary Shares”) (or pre-funded warrants
to purchase Ordinary Shares in lieu thereof (“Pre-Funded Warrants”)) and (ii) warrants to purchase up to 5,703,462
Ordinary Shares (the “Ordinary Warrants”, and together with the Pre-Funded Warrants, the “Warrants”),
at a combined purchase price of $1.315 per Ordinary Share (or $1.314 per Pre-Funded Warrant) and accompanying Ordinary Warrant, pursuant
to the Company’s effective shelf registration statement on Form F-3 (File No. 333-286956) and a related base prospectus, together
with the related prospectus supplement, dated as of November 14, 2026 (such registration statement, prospectus and prospectus supplement,
collectively, the “Registration Statement”), filed with the Securities and Exchange Commission. At the initial closing,
the Company issued an aggregate of 380,232 Ordinary Shares and Ordinary Warrants to purchase up to 380,232 Ordinary Shares. Pursuant
to the Securities Purchase Agreement, the Investors have also irrevocably committed, subject only to the continued listing of the Ordinary
Shares on Nasdaq or another U.S. national securities exchange, to purchase an additional $7.0 million of Ordinary Shares (or Pre-Funded
Warrants in lieu thereof) and accompanying Ordinary Warrants at the same price in 10 monthly closings of $0.7 million each, scheduled
to occur from December 1, 2026 through September 1, 2027. Certain of the subsequent closings may be postponed until the Company’s
receipt of shareholder approval of an increase in its authorized share capital, and any subsequent closing may be postponed if the Registration
Statement is not then available.
The
Ordinary Warrants have an exercise price of $1.578 per Ordinary Share, are immediately exercisable and will expire three years following
the initial closing date, including Ordinary Warrants issued at the subsequent closings. Each Pre-Funded Warrant has an exercise price
of $0.001 per Ordinary Share, is immediately exercisable and may be exercised at any time and has no expiration date. The Ordinary Warrants
and the Pre-Funded Warrants are subject to customary adjustments; however, no such warrants contain any “ratchet” or other
financial antidilution provisions. None of the Warrants may be exercised if the aggregate number of Ordinary Shares beneficially owned
by the holder thereof, together with its affiliates and any person acting as a group with the holder or its affiliates, would exceed 19.99% immediately after exercise thereof.
The
Offering was made directly by the Company, without a placement agent, underwriter, broker or dealer, and no placement agent fees are
payable. The initial closing of the Offering occurred on November 17, 2026.
The
gross proceeds from the initial closing of the Offering were approximately $0.5 million, and the aggregate gross proceeds from the Offering,
assuming all subsequent closings are completed, will be approximately $7.5 million, in each case before deducting estimated expenses
relating to the Offering and excluding any proceeds from the exercise of the Ordinary Warrants. The Company intends to use the net proceeds
from the Offering for clinical, regulatory, manufacturing, and research and development activities; potential acquisitions and in-licensing;
and other general corporate purposes.
The
Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally,
the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement.
The
foregoing description of the Securities Purchase Agreement, the Ordinary Warrants and the Pre-Funded Warrants is only a summary and is
qualified in its entirety by reference to the complete text of the form of Securities Purchase Agreement, the form of Ordinary Warrant
and the form of Pre-Funded Warrant, copies of which are attached as Exhibit 10.1, Exhibit 4.1 and Exhibit 4.2, respectively, to this
Report on Form 6-K and are incorporated by reference herein, and such description and exhibits are incorporated by reference into the
Company’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799,
File No. 333-232413,
File No. 333-232009,
File No. 333-252926,
File No. 333-286956, File No.
333-292417, File No. 333-294284,
File No. 333-295215 and File
No. 333-298071), filed with
the Securities and Exchange Commission.
Copies
of the opinion of FISCHER (FBC & Co) regarding the validity of the Ordinary Shares issued at the initial closing and the Ordinary
Shares issuable upon exercise of the Ordinary Warrants issued at the initial closing, and the opinion of Greenberg Traurig, LLP regarding the validity of the
Warrants are filed as Exhibit 5.1 and Exhibit 5.2, respectively, to this Report on Form 6-K and are incorporated by reference into
the Company’s registration statement on Form F-3 (File No. 333-286956) filed with the Securities and Exchange
Commission.
Neither
this Report on Form 6-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities
described herein or therein.
| Exhibit Number |
|
Description |
| 4.1 |
|
Form of Ordinary Warrant |
| 4.2 |
|
Form of Pre-Funded Warrant |
| 5.1 |
|
Opinion of FISCHER (FBC
& Co) |
| 5.2 |
|
Opinion of Greenberg Traurig, LLP |
| 10.1 |
|
Form of Securities Purchase Agreement |
| 23.1 |
|
Consent of FISCHER (FBC
& Co) (set forth in Exhibit 5.1) |
| 23.2 |
|
Consent of Greenberg Traurig, LLP (set forth in Exhibit 5.2) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Enlivex Ltd. |
| |
(Registrant) |
| |
|
| |
By: |
/s/
Oren Hershkovitz |
| |
Name: |
Oren Hershkovitz |
| |
Title: |
Chief Executive Officer |
Date:
November 17, 2026